Gain Therapeutics, Inc. GANX
As ofNov 20, 2026, 2:58 PM EST
- YTD
- -68.80%
- 1 year
- -64.75%
5D 0.00 (0.00%)
- Market cap
- 44.73M
- EPS (ttm)
- -0.42
- Shares out
- 26.53M
- Forward P/E
- -1.76
- YTD return
- -68.80%
- 1-year return
- -64.75%
- 50-day average
- 2.05
- 200-day average
- 2.12
- Volume
- 451.52K
- Avg volume
- 545.81K
- Open
- 1.02
- Previous close
- 1.05
- Day's range
- 1.00 – 1.10
- 52-week range
- 0.94 – 4.34
- Beta
- 0.34
- Price target
- 7.33 (+630.0%)
Key statistics
- Enterprise value
- 30.98M
- Price / book
- 2.02
- Free cash flow
- -10.06M
- Total cash
- 16.94M
- Total debt
- 807.57K
- Return on equity
- -188.83%
- Short % of float
- 2.71%
Fundamental scorecard
4 of 25 checks passed on GANX’s reported financials
4of 25 checks passed
- Value 0 of 5
- Growth 1 of 5
- Profitability 0 of 5
- Financial health 3 of 5
- Dividend 0 of 5
Statements to Sep 30, 2026.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 14, 2024 | Sep 1, 2024 | -0.23 | -0.17 | +0.06 | +26.09% |
| Aug 8, 2024 | Jun 1, 2024 | -0.31 | -0.42 | -0.11 | -35.48% |
| Aug 8, 2024 | Jun 1, 2024 | -0.31 | — | — | — |
| May 14, 2024 | Mar 1, 2024 | -0.30 | -0.22 | +0.08 | +26.67% |
| May 14, 2024 | Mar 1, 2024 | -0.30 | — | — | — |
| Mar 26, 2024 | Dec 1, 2023 | -0.32 | -0.29 | +0.03 | +9.38% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Dec 5, 2024 | Roth MKM | init | — | Buy |
| Nov 25, 2024 | HC Wainwright & Co. | reit | Buy | Buy |
| Oct 9, 2024 | HC Wainwright & Co. | reit | Buy | Buy |
| Oct 1, 2024 | HC Wainwright & Co. | reit | Buy | Buy |
| Sep 3, 2024 | HC Wainwright & Co. | reit | Buy | Buy |
| Aug 9, 2024 | Chardan Capital | main | Buy | Buy |
About Gain Therapeutics, Inc.
Gain Therapeutics, Inc., a biotechnology company, develops novel small molecule therapeutics to treat diseases across various therapeutic areas. Its drug discovery platform Magellan discovers novel allosteric binding sites in a disease; identifies proprietary small molecules that bind these sites to modulate protein function; and treats the underlying cause of the disease. The company's lead drug candidate, GT-02287 for the treatment of GBA1 Parkinson's disease is being evaluated in a Phase I clinical trials. It has various small molecule drug candidates, which are in the discovery, research, and preclinical stages for the treatment of Dementia with Lewy Bodies, Alzhiemer's Disease, Gaucher, GM1 Gangliosidosis, Krabbe Disease, Alpha1-Antitrypsun deficiency, and solid tumors. The company was founded in 2017 and is headquartered in Bethesda, Maryland.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- gaintherapeutics.com
News
Gain Therapeutics Presents Clinical Data from Phase 1b Study of Rexaceract and Preclinical Data from Novel GCase Modulator GT-04686
12 Health Care Stocks Moving In Tuesday's Intraday Session
Gain Therapeutics (GANX) Upgraded to Buy: Here's What You Should Know Gain Therapeutics Q3 EPS $(0.07) Beats $(0.12) Estimate
Your note
Sign in to keep a note on GANX — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| ALDER MATTHIAS | Chief Executive Officer | Conversion of Exercise of derivative security | Mar 25, 2024 | 21,140 |
| ISLAM KHALID | Officer and Director | Purchase | Aug 8, 2024 | 930,784 |
| MACK GENE C | Chief Executive Officer | Purchase | Aug 8, 2024 | 14,400 |
| RICHMAN ERIC I. | Director | Purchase | Jun 30, 2024 | 304,458 |
| RILEY JEFFREY SCOTT | Director | Purchase | Mar 27, 2024 | 30,000 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| DME Capital Management, LP | 2.13% | 566,130 | 888.82K | Sep 29, 2024 |
| Gotham Asset Management, LP | 1.26% | 334,592 | 525.31K | Sep 29, 2024 |
| Geode Capital Management, LLC | 1.03% | 271,972 | 427.00K | Sep 29, 2024 |
| Vanguard Group Inc | 0.55% | 145,217 | 227.99K | Sep 29, 2024 |
| Blackrock Inc. | 0.32% | 84,924 | 133.33K | Sep 29, 2024 |
| Jones Financial Companies, L.L.L.P. | 0.20% | 53,500 | 84.00K | Sep 29, 2024 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Fidelity Extended Market Index Fund | 0.54% | 143,522 | 225.33K | Oct 30, 2024 |
| Vanguard Extended Market Index Fund | 0.51% | 135,702 | 213.05K | Sep 29, 2024 |
| Fidelity Total Market Index Fund | 0.21% | 56,624 | 88.90K | Oct 30, 2024 |
| iShares Micro Cap ETF | 0.15% | 38,783 | 60.89K | Oct 30, 2024 |
| Fidelity Series Total Market Index Fund | 0.13% | 34,738 | 54.54K | Oct 30, 2024 |
| Fidelity NASDAQ Composite Index Fund | 0.04% | 10,062 | 15.80K | Oct 30, 2024 |
